COMMUNIQUÉS West-GlobeNewswire

Alembic Therapeutics LLC Announces the Launch of PIVYA® (pivmecillinam)
18/02/2026
Pivya ® (pivmecillinam) Tablets, 185mg Now Available by Prescription in the United States BEDMINSTER, N.J., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Alembic Therapeutics is pleased to announce the U.S. availability of Pivya [...]
Stoked Bio Secures Exclusive Global License to Develop a Promising New Therapy for Crohn’s Disease
18/02/2026
Enterololin, a narrow-spectrum antibiotic uses a novel mechanism of action to attack the infection HAMILTON, Ontario, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Stoked Bio Inc., a Canadian biotechnology company focused on the [...]
Notice to Convene the Annual General Meeting of Genmab A/S
18/02/2026
Company Announcement Genmab A/S to hold Annual General Meeting on Thursday March 19, 2026 COPENHAGEN, Denmark; February 18, 2026 – Genmab A/S (Nasdaq: GMAB) summons the Annual General Meeting on Thursday, March 19, 2026 [...]
Vaxart to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026
18/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral vaccines based on its proprietary delivery platform, today [...]
Humacyte Announces Presentation of Symvess® Long-Term Safety and Efficacy Results at VESS Meeting
18/02/2026
- Data presented at Annual Winter Meeting 2026 for the Vascular & Endovascular Surgery Society - - After up to 36 months of follow-up, extremity arterial trauma patients had high rates of limb salvage, low rates of [...]
Prenetics Reports Record Q4 and FY 2025 Results: IM8 Achieves $120M ARR¹ in 12 Months, Revenue Surges 480% YoY
18/02/2026
Total Revenue Increased 480% to $92.4 million for Full Year 2025, Q4 Revenue reached $36.6 million IM8 Reaches $10 Million in Monthly Revenue in December 2025, Achieving $120M ARR Milestone Strategic Transformation [...]
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Key IP Portfolio Advancements Align with Biotech Asset Trend
18/02/2026
NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic [...]
Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need
18/02/2026
Stenoparib is being evaluated in combination with temozolomide clinical benefit in relapsed Small Cell Lung Cancer Trial is fully funded by the U.S. Department of Veterans Affairs and is open for enrollment at 11 VA [...]
Apyx Medical Corporation to Participate in The Citizens Life Sciences Conference
18/02/2026
CLEARWATER, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion ® and the AYON Body [...]
Unnatural Products Announces Licensing Agreement with Novartis to Develop Macrocyclic Peptide Therapeutics
18/02/2026
Collaboration will harness UNP’s AI enhanced macrocycle platform to drug historically “undruggable” targets SANTA CRUZ, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Unnatural Products, Inc. (UNP), a biotech developing [...]
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
18/02/2026
SAN DIEGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib [...]
Axsome Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
18/02/2026
NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it [...]
Helsinn announces European Commission approval of AKYNZEO® Oral Suspension
18/02/2026
Lugano, Switzerland – February 18th, 2026 – Helsinn Healthcare SA (“Helsinn”), a global pharmaceutical group focused on supporting patients with cancer and chronic diseases, today announced that the European Commission [...]
Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer
18/02/2026
Board-certified allergist and leading food allergy and anaphylaxis researcher joins Aquestive to support Anaphylm™ (dibutepinephrine) sublingual film NDA resubmission and pipeline WARREN, N.J., Feb. 18, 2026 (GLOBE [...]
NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update
18/02/2026
-- Approval decisions from EMA, UK and Switzerland regulators for obicetrapib and obicetrapib/ezetimibe fixed dose combination expected in 2H26 -- -- Phase 3 PREVAIL CVOT blinded event rate tracking in line with [...]
CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral Sclerosis
18/02/2026
Neflamapimod endorsement based on targeted mechanism of action, demonstrated clinical activity in neurodegenerative diseases, and encouraging translational data in ALS-relevant neurotoxicity models UK-based trial first [...]
Tilray Brands and the Carlsberg Group Enter into an Exclusive Multi-Year U.S. Brewing and Commercial Partnership
18/02/2026
NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY), a leading global consumer packaged goods company and the fourth-largest craft beer brewer in the United States, today announced [...]
Tango Therapeutics to Report Fourth Quarter 2025 Financial Results and Participate in Three Upcoming Investor Conferences
18/02/2026
BOSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report fourth quarter 2025 financial results on March 5, 2026, before the open of the U.S. financial [...]
Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit
18/02/2026
CAMBRIDGE, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact [...]

Pages